Investor Presentaiton

Phase II Program Initiated: "Extra Strength" Dose for Extended Duration Phase II Duration Study Initiation Increased clinical duration in a 900 kDa has been shown in published clinical data¹ Study initiated in Q4'21 with first patient enrollment expected in Q1′22 Study Design Double blind, randomized, controlled, prospective Three arms: 20U Botox® Cosmetic, 20U JeuveauⓇ vs 40U "extra strength" JeuveauⓇ Up to 1 year follow up Study Initiation Activities 1Q 2022 First Patient Enrolled 2022 Clinical Study 2023 1H 2023 Study Completed 1. Kaufman-Janette, J., Cox, S. E., Dayan, S., & Joseph, J. (2021). Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?. Toxins, 13(7), 494. https://doi.org/10.3390/toxins13070494 в 8 16

View entire presentation